Quick Answer
INTENSITY THERAPEUTICS, INC. reported Research And Development Expense of $6.79 million for the year ending 2025.
- INTENSITY THERAPEUTICS, INC. showed a decrease of -35.4% in Research And Development Expense from 2024 to 2025.
- This data is from INTENSITY THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $1.39 million | Q3 2022: $1.16 million | Q1 2023: $774.0 thousand | Q2 2023: $859.0 thousand | Q3 2023: $1.35 million | Q1 2024: $2.82 million | Q2 2024: $3.56 million | Q3 2024: $2.15 million | Q1 2025: $2.19 million | Q2 2025: $1.54 million | Q3 2025: $1.55 million.
- Over the full 4 years of available data (2022 to 2025), INTENSITY THERAPEUTICS, INC.'s Research And Development Expense has grown by 32.2%.
- Historical annual values: Fiscal year 2025: $6.79 million | Fiscal year 2024: $10.50 million | Fiscal year 2023: $4.79 million | Fiscal year 2022: $5.13 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: